Introduction
The serpin-enzyme complex (SEC) receptor mediates catabolism of a1-antitrypsin (a1-AT)-elastase complexes and increases in synthesis of a,-AT in cell culture. The SEC receptor recognizes a pentapeptide domain on a1-AT-elastase complexes (a,-AT 370-374), and the same domain in several other serpins, amyloid-,8 peptide, substance P, and other tachykinins.
Thus, it has also been implicated in the biological properties of these ligands, including the neurotoxic effect of amyloid-,B peptide. In this study, we examined the possibility that the SEC receptor mediates the previously described neutrophil chemotactic activity of a1-AT-elastase complexes, and whether the other ligands for the SEC receptor have neutrophil chemotactic activity. The results show that 125I-peptide 105Y (based on a,-AT 359-374) binds specifically and saturably to human neutrophils, and the characteristics of this binding are almost identical to that of monocytes and hepatoma-derived hepatocytes. Peptide 105Y and amyloid-/i peptide mediate chemotaxis for neutrophils with maximal stimulation at 1-10 nM. Mutant or deleted forms of peptide 105Y, which do not bind to the SEC receptor, have no effect. The neutrophil chemotactic effect of a1-AT-elastase complexes is blocked by antiserum to peptide 105Y and by antiserum to the SEC receptor, but not by control antiserum. Preincubation of neutrophils with peptide 105Y or substance P completely blocks the chemotactic activity of amyloid-,B peptide, but not that of FMLP. These results, therefore, indicate that the SEC receptor can be modulated by homologous desensitization and raise the possibility that pharmacological manipulation of this receptor will modify the local tissue response to inflammation/injury and the neuropathologic reaction of Alzheimer's disease. (J. Clin (9) . Through a homologous pentapeptide domain, several other serpin-enzyme complexes, the amyloid-# peptide, bombesin, and tachykinins also bind to the SEC receptor (10) . In the current study, we examined the possibility that this receptor also mediates the neutrophil chemotactic activity of a1-AT-elastase complexes, and whether other ligands, such as the amyloid-f peptide, are chemotactic via activation of the SEC receptor.
Methods
Materials. Peptides 105Y, 105C, and 105C-C, and amyloid-f peptide 25-35 were synthesized by the solid phase method, purified, and subjected to amino acid composition and sequence analysis, as previously described (8 Chemotaxis. Chemotaxis was determined in modified Boyden chambers, as previously described ( 12) . Briefly, 1.2 x 106 neutrophils/ ml were placed in the upper compartment and separated from chemoattractants in the lower compartment by a 2-Mm pore size filter (Nucleopore Corp., Pleasanton, CA) overlaying a 0.45 gm pore size filter (Millipore Corp., Bedford, MA). After 1 h the chambers were disassembled and the membranes were stained with hematoxylin. Chemotaxis was quantified by counting at high dry magnification (X400) the number of cells that migrated to the interface between the membranes (expressed as cells per high power grid). Five fields were counted for each experiment. The number of cells migrating in the control was considered background and subtracted for the final reported results. Experiments were performed in triplicate.
For experiments in which the neutrophil chemotactic effects of al-AT-elastase complexes are blocked by antisera, the a,-AT-elastase complexes were prepared according to the previously described protocol (8) . Antiserum to keyhole-limpet hemocyanin-coupled peptide lO5Y was prepared by hyperimmunizing New Zealand White rabbits. Specific antibody titers were determined by ELISA. First, we examined the possibility that the SEC receptor was expressed on human neutrophils (Figs. 1 B and 1 C). Human neutrophils were purified from normal donor blood. The expression of the SEC receptor on neutrophils was assessed by radioligand binding assays (Fig. 1 B) using a synthetic 1251-labeled peptide 105Y (SIPPEVKFNKPFVYLI) derived from a,-AT sequence 359-374. A saturation binding curve from one donor is shown in Fig. 1 number has been -13,000 in one and 400,000-500,000 in two of these. Next, we examined the possibility that peptide 105Y is chemotactic for neutrophils (Fig. 2 A) . Neutrophils were placed in the upper compartment of modified Boyden chambers separated from peptide 105Y, FMLP, or solvent medium by a 2-Am pore filter overlaying a 0.45-Mm pore filter. Peptide 105Y elicited chemotaxis with maximal stimulation at a concentration of l0 O-M. The solvent in these experiments (DMSO) did not stimulate migration ofneutrophils. The magnitude ofthe effect was comparable in potency to that of 10 -8 M FMLP. The specificity of this effect was further examined with the shorter synthetic peptides 105C and 105C-C (Fig. 2 B) . Pentapeptide Figure 3 . Effect of specific antibodies on neutrophil chemotactic effect of a1-AT-elastase complexes. Chemotaxis assays were performed as described above with a,-AT-elastase complexes in three different concentrations ( I0 9-I0 7 M) or f-Met-Leu-Phe (FLMP) in one concentration ( 10-8 M) as the putative chemotactic factors. In each case, the putative chemotactic factor was put in the lower chamber in medium alone (solid bars) or in medium supplemented with rabbit antiserum to peptide lO5Y in a 1:50 dilution (hatched bars). In separate samples the putative chemotactic factor was put in the lower chamber in medium alone and the neutrophils added to the upper chamber in medium containing a control antiserum (rabbit antiserum to guinea pig C3 [ open bars] ) or the neutrophils added to the upper chamber in medium containing anti-SEC receptor antiserum in a 1:50 dilution (dotted bars). m Medium alone; o medium + control antiserum; a medium + anti-peptide antiserum; o medium + anti-receptor antiserum. 
105C (FVYLI) corresponds to the minimal SEC receptorbinding domain of a,-AT-elastase complexes (4). Peptide
105C-C (FVYL) lacks the carboxyl-terminal residue ofpeptide 105C and does not bind to the SEC receptor. Peptide 105C stimulated migration of neutrophils with a maximal effect at 10-1 M peptide. Peptide 105C-C had no effect (Fig. 2 B) . The specificity ofthe chemotactic activity was, therefore, consistent with the specificity of the SEC receptor.
To further demonstrate that the chemotactic property of a1-AT-elastase complexes was mediated by the SEC receptor, we examined the possibility that the property could be blocked by specific antiserum to peptide lO5Y or antiserum to the SEC receptor (Fig. 3) . First, neutrophils were placed in the upper compartments of a modified Boyden chamber separated from a,-AT-elastase complexes in the lower compartment. a1-ATelastase complexes elicited directed migration with maximal stimulation at a concentration of 10-8 M a I-AT initially added to the reaction mixture. This is a somewhat higher effective concentration than that required with synthetic peptides (Fig.  2) . However, it is not possible to determine whether this difference is real or apparent because the actual concentration of ligand presented to the binding site by the a I-AT-elastase complex reaction mixture cannot yet be measured. The magnitude ofthe chemotactic effect of a1-AT-elastase complexes was comparable in potency to that of FMLP. The chemotactic effect of a1-AT-elastase complexes, but not that of FMLP, was completely blocked by coadministration of anti-peptide 105Y in the lower compartment (Fig. 3) . Moreover, the effect of a1-AT-elastase complexes was completely blocked when neutrophils were preincubated with antiserum to the SEC receptor, but not when preincubated with a control antiserum.
We next examined the possibility that other ligands for the SEC receptor, such as amyloid-fl peptide, had neutrophil chemotactic properties and whether these properties could be desensitized (Fig. 4) . In a previous study, we have shown that amyloid-f peptide binds to the SEC receptor ( 10). In our subsequent studies, we have shown that amyloid-3 peptide 25-35 and 30-35 bind to the SEC receptor as well as amyloid-f peptide 1-42 (Joslin, G., R. J. Fallon, and D. H. Perlmutter, unpublished results), thereby localizing the receptor binding domain to the pentapeptide region which is most homologous to substance P, peptide lO5Y, and a,-AT sequences. Here, we used amyloid-3 peptide 25-35 and found it to elicit robust neutrophil chemotaxis, maximal at 10-'-o0-8 M, and completely abrogated by pretreatment with peptide 105Y (Fig. 4 A) . Moreover, the neutrophil chemotactic effect of amyloid-3 peptide was completely abrogated by preincubation of the neutrophils with substance P (Fig. 4 B) . Preincubation of neutrophils with peptide 105Y or substance P did not block the chemotactic effect of FMLP. Accordingly, peptide 105Y, amyloid-3 peptide, and substance P bind to the same receptor on neutrophils, elicit potent chemotactic responses at low receptor occupancy, and elicit homologous desensitization of the SEC receptor. 1152 Joslin, Griffin, August, Adams, Fallon, Senior, and Perlmutter Although it has not been emphasized in the description of Alzheimer's disease, several studies have reported an inflammatory response surrounding amyloid plaques. In studies of immune associated antigens in human postmortem samples, several reports show expression of HLA-DR major histocompatibility antigen on microglial cells adjacent to amyloid plaques (20) . Moreover, microglial cell proliferation and scavenging activity, as well as T cell infiltration, was reported at plaque sites (21 ) . Because the SEC receptor has been demonstrated on the surfaces of cells of myeloid lineage, including monocytes and neutrophils, it is possible that SEC receptor expression on microglial cells plays a role in this local inflammatory response. Taken together with the previous observations about Alzheimer's disease, the present report suggests the working hypothesis that the SEC receptor plays a role in the pathophysiology of this disease by mediating clearance and intracellular proteolysis of the amyloid-,B peptide, a neurotrophic/ neurotoxic effect of the amyloid-,B peptide, and/or a local inflammatory response to the amyloid-3 peptide. 
